Dopamine Agonists
2 Citations•2001•
P. Tuite, B. Ebbitt
SEMINARS IN NEUROLOGY,
The disadvantages of dopamine agonists as compared with levodopa therapy are outlined and the features and costs of the four Food and Drug Administration-approved agonists and apomorphine are discussed.
Abstract
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ropinirole) and apomorphine, another agonist presently under investigation, are discussed.